Is (1,3)-β-D-glucan useless to guide antifungal therapy in ICU?
- PMID: 35771251
- DOI: 10.1007/s00134-022-06766-2
Is (1,3)-β-D-glucan useless to guide antifungal therapy in ICU?
Comment on
-
(1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.Intensive Care Med. 2022 Jul;48(7):865-875. doi: 10.1007/s00134-022-06733-x. Epub 2022 Jun 16. Intensive Care Med. 2022. PMID: 35708758 Free PMC article. Clinical Trial.
References
-
- Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M et al (2014) Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40:1303–1312. https://doi.org/10.1007/s00134-014-3408-3 - DOI - PubMed - PMC
-
- Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M et al (2019) Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care Lond Engl 23:219. https://doi.org/10.1186/s13054-019-2497-3 - DOI
-
- Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis Off Publ Infect Dis Soc Am 54:1739–1746. https://doi.org/10.1093/cid/cis305 - DOI
-
- Leroy O, Bailly S, Gangneux J-P, Mira J-P, Devos P, Dupont H et al (2016) Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care 6:2. https://doi.org/10.1186/s13613-015-0103-7 - DOI - PubMed - PMC
-
- Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284–1292. https://doi.org/10.1093/cid/cit006 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources